The present invention relates to epidermal growth factor receptor (EGFR) inhibitor, fibroblast growth factor receptor (FGFR) inhibitor, Aurora kinase inhibitor, protein kinase A (PKA) inhibitor, protein kinase C (PKC) inhibition One or more kinase inhibitors selected from the group consisting of drugs, MEK inhibitors, Met inhibitors, JNK inhibitors, Syk inhibitors and JAK inhibitors, prostaglandin analogs, estrogen receptor antagonists, or Tivozanib and Its analogs, SB 216763, Cdk2 Inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL, AMODIAQUINE, SU9516, Sunitinib and its analogs, GSK-3 Inhibitor XIII, Bisindolylmaleimide I, HYDROQUINONE, FLUNISOLIDE, MGCD-3265 -monoxime, HYDRASTINE (1R, 9S), PIPERINE, BUTAMBEN, Axitinib and its analogs, APOMORPHINE, FENBUFEN, Bosutinib (SKI-606) and its analogs, Wee1 Inhibitor, Cdk2 Inhibitor IV, NU6140, 3-hydroxy Provided is a prophylactic and / or therapeutic agent for amyotrophic axon sclerosis (ALS) containing one or more compounds selected from the group consisting of cybutyric acid, AT9283, Imatinib, Nilotinib, Rebastinib, and Buffettinib. In particular, by using a compound that is already on the market as a pharmaceutical, it is possible to develop a drug for the prevention and treatment of ALS quickly and at low cost.本発明は、上皮細胞増殖因子受容体（EGFR）阻害薬、線維芽細胞増殖因子受容体（FGFR）阻害薬、Auroraキナーゼ阻害薬、プロテインキナーゼA（PKA）阻害薬、プロテインキナーゼC（PKC）阻害薬、MEK阻害薬、Met阻害薬、JNK阻害薬、Syk阻害薬及びJAK阻害薬からなる群より選択される１以上のキナーゼ阻害薬、プロスタグランジン類似体、エストロゲン受容体アンタゴニスト、あるいは、Tivozanibおよびその類縁体、SB 216763、Cdk2 Inhibitor II、BUDESONIDE、RIBOFLAVIN、alpha-TOCHOPHEROL、AMODIAQUINE、SU9516、Sunitinibおよびその類縁体、GSK-3 Inhibitor XIII、Bisindolylmaleimide I、HYDROQUINONE、FLUNISOLIDE、MGCD-265、Indirubin-3'-monoxime、HYDRASTINE (1R, 9S)、PIPERINE、BUTAMBEN、Axitinibおよびその類縁体、APOMORPHINE、FENBUFEN、Bosutinib(SKI-606)およびその類縁体、Wee1 Inhibitor、Cdk2 Inhibitor IV, NU6140、3-ヒドロキシ酪酸、AT9283、Imatinib、Nilotinib、Rebastinib、並びにBafetinibからなる群より選択される１以上の化合物を含有する、筋委縮性軸索硬化症（ALS)の予防及び／又は治療剤を提供する。特に医薬品として既に上市されている化合物を用いることで、迅速かつ低コストで、ALS
